MoonLake Immunotherapeutics’ (MLTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) in a report released on Tuesday,Benzinga reports. The brokerage currently has a $32.00 price target on the stock.

Other analysts have also issued research reports about the company. UBS Group set a $24.00 price objective on MoonLake Immunotherapeutics in a research note on Friday, January 9th. Zacks Research downgraded MoonLake Immunotherapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 20th. The Goldman Sachs Group cut shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $8.00 to $10.00 in a research report on Wednesday, January 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a research report on Wednesday, October 8th. Finally, Citigroup downgraded shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a report on Wednesday, October 29th. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $25.77.

MoonLake Immunotherapeutics Stock Performance

NASDAQ MLTX opened at $14.77 on Tuesday. The firm has a market capitalization of $948.68 million, a P/E ratio of -4.45 and a beta of 1.21. The company has a current ratio of 8.50, a quick ratio of 8.50 and a debt-to-equity ratio of 0.25. The firm’s fifty day moving average price is $14.70 and its two-hundred day moving average price is $27.29. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same quarter in the prior year, the company earned ($0.56) EPS. As a group, research analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Insider Transactions at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 130,000 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the chief executive officer owned 2,948,577 shares in the company, valued at $44,464,541.16. This represents a 4.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Kristian Reich sold 130,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the insider directly owned 72,908 shares in the company, valued at $1,099,452.64. This represents a 64.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 402,908 shares of company stock worth $5,987,162. 12.02% of the stock is owned by insiders.

Institutional Trading of MoonLake Immunotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. UBS Group AG increased its stake in MoonLake Immunotherapeutics by 183.4% in the fourth quarter. UBS Group AG now owns 239,020 shares of the company’s stock valued at $3,150,000 after acquiring an additional 154,673 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of MoonLake Immunotherapeutics by 129.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,592 shares of the company’s stock valued at $179,000 after purchasing an additional 7,673 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of MoonLake Immunotherapeutics by 24.9% during the 4th quarter. SG Americas Securities LLC now owns 21,888 shares of the company’s stock worth $288,000 after buying an additional 4,362 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of MoonLake Immunotherapeutics by 342.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 174,161 shares of the company’s stock worth $1,249,000 after buying an additional 134,764 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in MoonLake Immunotherapeutics in the third quarter valued at about $28,000. Institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.